";s:4:"text";s:4226:" Simply log in to access the full article, or register for free if you do not yet have a username and password.Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?.Transection of the oesophagus for bleeding oesophageal varices.The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects.A new equation to estimate glomerular filtration rate.KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.Guidance for Industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling.Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function.Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Standardization of chemotherapy and individual dosing of platinum compounds.Clinical pharmacokinetics of oxaliplatin: a critical review.High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.A synopsis of clinical pharmacokinetic alterations in advanced CKD.Pharmacokinetics and dosage adjustment in patients with renal dysfunction.Hemodialysis acutely improves hepatic CYP3A4 metabolic activity.Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin.Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.Global prevalent use, trends and practices in haemodiafiltration.High-flux or low-flux dialysis: a positition statement following publication of the Membrane Permeability Outcome study.Effective clearance of methotrexate using high-flux hemodialysis membranes.Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.Guideline on the evalution of the pharmacokinetics of medicinal products in patients with impaired hepatic function.Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling.Part II: liver function in oncology: towards safer chemotherapy use.Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.Part I: liver function in oncology: biochemistry and beyond.Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response.Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. ";s:7:"keyword";s:63:"dosage adjustment for cytotoxics in hepatic impairment provigil";s:5:"links";s:3976:"Tenofovir Preço Geriforte,
Kenacort Injection Use Singulair,
Methylprednisolone Sinus Infection,
Can Keppra Be Crushed Propecia,
Cortef And Alcohol Zetia,
Qsymia Stopped Working Brand Retino-a Cream,
Management Of Drug Interactions Pdf Isoptin,
Imipramine Side Effects Amoxil,
Ham Megalis,
Ivermectin For Dogs Dosage In Ml Imdur,
Pumpkin Seeds For Overactive Bladder Dostinex,
Viagra Headache Reddit Minomycin,
Dangers From Using An Expired Albuterol Inhaler Lithium,
Laryngeal Paralysis Treatment Without Surgery Erythromycin,
Sumatriptan Canada Price Viagra Flavored,
Prazosin First Trimester Finpecia,
Lamotrigine Bipolar Aygestin,
Camphor Basil Seeds Prometrium,
Oral Cyclophosphamide Side Effects Levaquin,
Where To Buy Jardiance Malegra Dxt,
Dangers Of Retinol Cream Amaryl,
Nitroglycerin Tablets Price In India Super P-force,
Antibiotics For Chest Infection Amoxicillin Rulide,
Bandy Syrup Uses In Kannada Hytrin,
Norvasc Otc,
Century Sun Plaza Grifulvin V,
Sabra Hummus Recall July 2020 Suprax,
Best Royal Jelly Mysoline,
Visine Allergy Eye Drops Side Effects Voltaren,
Medications To Stop Before Hip Replacement Surgery Levitra Professional,
Medication And Elderly Sinemet,
Still Having Discharge After Bv Treatment Mentat,
";s:7:"expired";i:-1;}